Sentences with phrase «than developing products»

These companies, which profit by legally enforcing patents they own rather than developing products, may benefit from a 31 August ruling at a US federal court of appeal in Washington DC.

It is so scary that some companies are trying to keep BPA in their products... why is making more money better than developing a product?

Not exact matches

«That growth potential could be greater than we think — if businesses find new ways to engage with [global value chains] and develop new products and processes to make them more productive and competitive,» Lane said.

On deck for this year: Taking the knowledge garnered from selling more than 20 million products and using it to develop a Bark & Co. - branded line of toys and treats.

«A mature business may decide to keep replicating what it's doing» rather than entering new markets or developing new products, says Davis.

Many land at Haxlr8r, an accelerator that has graduated more than 50 companies using a now - familiar model: Learn the basics of manufacturing and develop a prototype; raise funds (and build buzz) in the United States through Kickstarter; manufacture the product; and drop - ship it anywhere in the world through the Pearl River Delta's unparalleled logistics networks.

Developing and marketing custom products is a riskier, more capital - intensive business than simply importing and exporting produce.

Small - business owners often spend too much time talking about the story behind their product and the difficulties they went through developing their business rather than homing in on their milestones and achievements.

If you develop a new technology, says Dixon, rather than selling or licensing it to the existing companies in that industry, consider building «a complete, end - to - end product or service that bypasses» them — from design to distribution.

(When they don't develop) a product or service that's more innovative and desirable than what your competitors are offering, and (when they don't) keep an eye on money coming in and going out so that you're not in a deficit, or if you are, coming up with a recovery plan and having the discipline to stay with it.»

Finally, and this is perhaps the most noteworthy point, I'm certain they would all agree that business and entrepreneurial success is based primarily on developing products and services that are far better at meeting critical customer needs than the competition.

Slowly but surely, tech vendors are recognizing that they not only have to be on point regarding product functionality and support, they must also make genuine human connections with customers — developing relationships that inspire more than a transactional bond between parties but instead build bonds based on trust and real human experiences.

Once a product is in the wild, customers contribute their own thoughts to the product, creating an experience that is better tailored to the end - user, rather than the team developing it.

Rather than continually running between store floor and stockroom, clerks could build expertise in products like those on the «It List» and develop more of a rapport with customers.

The fact is, it is often less costly for them to purchase your goods, services or in some cases, acquire your entire company, than it is to allocate a team and develop a new product from scratch.

OXO typically does not sign confidentiality agreements, Lee explained, because the company is developing more than 200 new products at any given time.

Rather than implementing UX as an afterthought, plan your UX strategy as you develop your product concept.

While Luis» education apps are less complex than the games he developed for Electronic Arts and Sony, he aimed to develop products that exceeded the ordinary and expected.

«At the time we had more products in the pipeline than we had money to develop them,» says Cornelius, who retired as CEO in 2010, though he remains chairman.

For example, Nanotech has developed a product called KolourOptik that it says is a better way of authenticating bank notes than the hologram technology we now use on our currency.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The cofounder and CEO of semiconductor and software maker Nvidia saw the future of computing more than a decade ago, and began developing products that could power the artificial intelligence era.

On the topic of business education, the Gallup study showed that African American, Asian, and Hispanic business owners were more likely than business owners in the general population to be extremely or very interested in learning how to build a strong business credit application, choose a credit product, and develop a business plan.

With competitors making lower - priced equipment, one interesting turn has been how VR tech has made its way into more ordinary products, rather than developing on a specialist - equipment trajectory.

That growth potential could be greater than we think — if businesses find new ways to engage with GVCs and develop new products and processes to make them more productive and competitive.

Toronto, July 27, 2011 — Eight Ontario companies have received more than $ 6 million in seed and later stage financing from the Investment Accelerator Fund (IAF), a program that invests in eligible companies as they develop their technologies and bring their products or services to market.

The dispute involves the drug Zarxio, an alternative that Sandoz developed to compete with Neupogen that sells for about 15 percent less than the original product.

Eight Ontario companies have received more than $ 6 million in seed and later stage financing from the Investment Accelerator Fund (IAF), a program that invests in eligible companies as they develop their technologies and bring their products or services to market.

More than 80 per cent of the retailer's products are designed and developed in Japan, South Korea, Singapore, Malaysia and China, countries known for innovation.

These risks and uncertainties include food safety and food - borne illness concerns; litigation; unfavorable publicity; federal, state and local regulation of our business including health care reform, labor and insurance costs; technology failures; failure to execute a business continuity plan following a disaster; health concerns including virus outbreaks; the intensely competitive nature of the restaurant industry; factors impacting our ability to drive sales growth; the impact of indebtedness we incurred in the RARE acquisition; our plans to expand our newer brands like Bahama Breeze and Seasons 52; our ability to successfully integrate Eddie V's restaurant operations; a lack of suitable new restaurant locations; higher - than - anticipated costs to open, close or remodel restaurants; increased advertising and marketing costs; a failure to develop and recruit effective leaders; the price and availability of key food products and utilities; shortages or interruptions in the delivery of food and other products; volatility in the market value of derivatives; general macroeconomic factors, including unemployment and interest rates; disruptions in the financial markets; risk of doing business with franchisees and vendors in foreign markets; failure to protect our service marks or other intellectual property; a possible impairment in the carrying value of our goodwill or other intangible assets; a failure of our internal controls over financial reporting or changes in accounting standards; and other factors and uncertainties discussed from time to time in reports filed by Darden with the Securities and Exchange Commission.

Overall, Munich Re has thus far been a more active investor and partner of tech startups engaging customers digitally and developing new approaches to insurance products than its rival.

The timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug.

«3D Signatures» timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug.»

The HSV - 1 test developed by Theranos retails for about $ 9.07, which makes it one of 100 products that Theranos sells for less than $ 10.

GFI argues that though it is true that plant - based products already exist, there may be significant room for the improvement of plant - based technology, and improving plant - based technology may yield shorter - term traction, i.e., greater market share, than the cultured foods.119 Recently developed plant - based products already seem to seem to represent improvements from past products; for example, the Impossible Burger, released in 2016, has received favorable reviews from vegans and omnivores alike.120 GFI's fostering and promotion of the development of similarly popular plant - based products could cause a significant reduction in the demand for animal products, particularly if they focus on plant - based chicken and fish and if they convince institutions to serve the plant - based products rather than animal products.121

GFI's innovation department has two primary areas of focus — firstly, encouraging scientists and entrepreneurs to join the plant - based and cultured meat industries, and secondly, supporting the ongoing success of existing companies in the industry.26 They have assembled a list of potential companies based on what they believe are promising ideas that have not been capitalized on, 27 and they have developed a list of more than 220 entrepreneurs and scientists, many of whom take part in monthly video calls led by GFI.28 In the last year, they have had some success in assisting in the founding of a plant - based meat company in India, Good Dot, and a plant - based fish company in the U.S., SeaCo.29 The companies have both raised millions in venture capital and are making progress towards competition with animal products.30 Although venture capitalist funding is a good indication that the companies themselves will be successful, and while the companies might not exist without GFI, it is unclear what portion of the responsibility for the companies» outcomes should be attributed to GFI.

They work with corporations to increase the availability of animal product alternatives and have developed a «restaurant report card» to score the top 100 chain restaurants according to their plant - based options.22 In general, we think that corporate outreach is a relatively effective animal advocacy intervention, though we are less certain of the effects of promoting plant - based options in restaurants than we are of the effects of working with corporations to implement welfare reforms.

By acquiring earth - spanning technologies, by developing products that can be produced anywhere and sold everywhere, by spreading credit around the world, and by connecting global channels of communication that can penetrate any village or neighborhood, these institutions we normally think of as economic rather than political.

There will come a time where these pious believers will do nothing else than go to church and pray to their god for new product developments to magically appear on trees, instead of going to college and practice science and engineering so that they can develop those new products themselves.

«We have been in business for more than 65 years and over that time we have developed an extensive library of formulas and flavors that make developing new products a much smoother process.»

«The company developed one of the first supply chains to bring quinoa to the United States,» Becker says, noting that the company now has more than 40 products that it sells in the United States.

The organic market in the People's Republic of China is enjoying continued growth, as more and more consumers are turning to products developed on environmental principles: with turnover of more than 5.8 billion USD in 2015, China is now the world's fourth - largest organic consumer market.

With more than 60 years of experience, the company is committed to developing the best, most flavorful meat products for its customers.

Of course, developing the best - tasting versions of these flavors and products requires the use of the best vanillas, and those supplied by Nielsen - Massey come with a more than 100 - year reputation for quality.

«In developing our presentation, we can tell why our product is different than anybody else.»

Food and Drink - July / August 2011 -(Page 166) > d DISTRIBUTORS Fresher than Fresh Redefining Fresh Fresher than Fresh developed an innovative seafood packaging system that preserves the product's freshness.

Coca - Cola Amatil is aiming to restore profit growth in its Australian beverages business by throwing its weight behind Brand Coke and Mt Franklin rather than developing new products and categories.

Data collected from more than 13,000 consumers in 21 countries forms the basis of an insight - driven new webinar from DuPont Nutrition & Health, designed to help manufacturers develop and market sports nutrition and weight management products.

DuPont Nutrition & Health has collected data from more than 14,000 consumers in 22 countries for an insight - driven research project designed to help manufacturers develop and market products in the health and wellness area.

New competition — often from high quality suppliers in developing regions — will make differentiating products and services more important than ever before.